Back to top
more

Alcon (ALC)

(Delayed Data from NYSE)

$78.84 USD

78.84
915,924

-0.73 (-0.92%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $78.87 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Integra's (IART) Codman EVD Catheter Study Data Favorable

by Zacks Equity Research

Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Alcon (ALC) Surgical End Market Grows, Vision Care Sales Rise

by Zacks Equity Research

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.

Stryker (SYK) Launches Autonomous Guidance System for Surgeries

by Zacks Equity Research

Stryker's (SYK) fully autonomous Ortho Q Guidance system offers smart and streamlined workflow, leading to enhanced procedural speed and efficiency.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

Acadia Healthcare (ACHC) Inks JV to Better Serve New Hampshire

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with New Hampshire-based SolutionHealth to build a behavioral health facility and address the dire need for advanced behavioral health services across the state.

Stryker (SYK) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

West Pharmaceutical (WST) Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

PacBio (PACB) Gets New Order for Revio System From Bioscientia

by Zacks Equity Research

PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Here's Why You Should Retain Molina (MOH) in Your Portfolio

by Zacks Equity Research

Numerous contract wins, financial flexibility and strong performing Medicaid and Medicare segments poise Molina (MOH) well for growth.

Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View

by Zacks Equity Research

Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Acadia Healthcare (ACHC) Expands With New Hospital in Michigan

by Zacks Equity Research

Acadia Healthcare's (ACHC) partnership with Bronson Healthcare to expand its footprint in Michigan with Bronson Behavioral Health Hospital.

Are Medical Stocks Lagging Alcon (ALC) This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Here's Why You Should Retain Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.

Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members

by Zacks Equity Research

Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.

Centene (CNC) to Provide Managed Care for SoonerSelect Program

by Zacks Equity Research

Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.

Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists

by Zacks Equity Research

For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.

Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up

by Zacks Equity Research

Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.

Alcon (ALC) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.